Search

Your search keyword '"Álvarez-Larrán A"' showing total 171 results
Start Over Author "Álvarez-Larrán A" Language english
171 results on '"Álvarez-Larrán A"'

1. Impact of somatic gene mutations on the risk of thrombosis in myelofibrosis

Author

Pastor-Galán, Irene, Pereira, Arturo, Arellano-Rodrigo, Eduardo, Martín, Iván, Mosquera-Orgueira, Adrián, Gómez-Casares, María-Teresa, Hernández-Sánchez, Alberto, Ferrer-Marín, Francisca, Mora, Elvira, Velez, Patricia, Ayala, Rosa, Angona, Anna, de las Heras, Natalia, Magro, Elena, Mata-Vázquez, María-Isabel, Fox, María-Laura, González de Villambrosía, Sonia, Ramírez, María-José, García, Ana, García-Gutiérrez, Valentín, Cáceres, Amparo, Durán, María-Antonia, Senín, María-Alicia, Raya, José-María, González, José Antonio, Cuevas, Beatriz, Xicoy, Blanca, Garrote, Marta, Ferrer, Blanca, Pérez-Encinas, Manuel, Hernández-Rivas, Jesús María, Bellosillo, Beatriz, Álvarez-Larrán, Alberto, and Hernández-Boluda, Juan Carlos

Published
2024
Full Text
View/download PDF

2. Integrating AIPSS‐MF and molecular predictors: A comparative analysis of prognostic models for myelofibrosis

Author

Adrián Mosquera‐Orgueira, Eduardo Arellano‐Rodrigo, Marta Garrote, Iván Martín, Manuel Pérez‐Encinas, María‐Teresa Gómez‐Casares, Alberto Hernández‐Sánchez, Francisca Ferrer‐Marín, Elvira Mora, Patricia Velez, Rosa Ayala, Anna Angona, Natalia de las Heras, Elena Magro, Carlos Pérez‐Míguez, Davide Crucitti, María‐Isabel Mata‐Vázquez, María‐Laura Fox, Sonia González de Villambrosía, María‐José Ramírez, Ana García, Valentín García‐Gutiérrez, Amparo Cáceres, María‐Antonia Durán, María‐Alicia Senín, José‐María Raya, José A. González, Beatriz Cuevas, Blanca Xicoy, Jyoti Nangalia, Jesús M. Hernández‐Rivas, Beatriz Bellosillo, Alberto Álvarez‐Larrán, Juan C. Hernández‐Boluda, and Spanish MPN Group (GEMFIN)

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2024
Full Text
View/download PDF

3. Philadelphia-negative chronic myeloproliferative neoplasm follow-up: when the phone rings. Changes during the COVID-19 pandemic and patient satisfaction. Experience in 30 health centers in Spain

Author

Ortuzar, Ariana, Fox, María Laura, Vera, Juan Antonio, Lorenzo Vizcaya, Álvaro, Marín Sánchez, Alberto, Llopis Calatayud, Inmaculada, Carbonell, Sara, Álvarez-Larrán, Alberto, Mata Serna, Raquel, Marco Buades, Josefa E., Quiroz Cervantes, Keina, Martínez Hellín, Ángela, Blum Domínguez, Alejandra, Caballero Navarro, Gonzalo, Cáceres Sansaloni, Amparo, Guerrero Fernández, Lucía, Muñoz Linares, Cristina, Gasior Kabat, Mercedes, Pérez López, Raúl, Fernández Rodríguez, Ángeles, Martínez Bilbao, Cristina, Cobo Rodríguez, María Teresa, Díaz, Álvaro, Durán, M. Antonia, Santaliestra Tomas, Marta, García-Gutierrez, Valentín, Magro Mazo, Elena, Hernández-Boluda, Juan Carlos, Segura, Adrián, Raya, José María, Navas Elorza, Begoña, and Osorio, Santiago

Published
2023
Full Text
View/download PDF

4. CNL and aCML should be considered as a single entity based on molecular profiles and outcomes

Author

Carreño-Tarragona, Gonzalo, Álvarez-Larrán, Alberto, Harrison, Claire, Martínez-Ávila, José Carlos, Hernández-Boluda, Juan Carlos, Ferrer-Marín, Francisca, Radia, Deepti H., Mora, Elvira, Francis, Sebastian, González-Martínez, Teresa, Goddard, Kathryn, Pérez-Encinas, Manuel, Narayanan, Srinivasan, Raya, José María, Singh, Vikram, Gutiérrez, Xabier, Toth, Peter, Amat-Martínez, Paula, Mcilwaine, Louisa, Alobaidi, Magda, Mayani, Karan, McGregor, Andrew, Stuckey, Ruth, Psaila, Bethan, Segura, Adrián, Alvares, Caroline, Davidson, Kerri, Osorio, Santiago, Cutting, Robert, Sweeney, Caroline P., Rufián, Laura, Moreno, Laura, Cuenca, Isabel, Smith, Jeffery, Morales, María Luz, Gil-Manso, Rodrigo, Koutsavlis, Ioannis, Wang, Lihui, Mead, Adam J., Rozman, María, Martínez-López, Joaquín, Ayala, Rosa, and Cross, Nicholas C. P.

Published
2023
Full Text
View/download PDF

5. Low-risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera

Author

Triguero, Ana, Pedraza, Alexandra, Pérez-Encinas, Manuel, Mata-Vázquez, María Isabel, Vélez, Patricia, Fox, Laura, Gómez-Calafat, Montse, García-Delgado, Regina, Gasior, Mercedes, Ferrer-Marín, Francisca, García-Gutiérrez, Valentín, Angona, Anna, Gómez-Casares, María Teresa, Cuevas, Beatriz, Martínez, Clara, Pérez, Raúl, Raya, José María, Guerrero, Lucía, Murillo, Ilda, Bellosillo, Beatriz, Hernández-Boluda, Juan Carlos, Sanz, Cristina, and Álvarez-Larrán, Alberto

Published
2022
Full Text
View/download PDF

6. Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations

Author

Marchetti, Monia, Vannucchi, Alessandro Maria, Griesshammer, Martin, Harrison, Claire, Koschmieder, Steffen, Gisslinger, Heinz, Álvarez-Larrán, Alberto, De Stefano, Valerio, Guglielmelli, Paola, Palandri, Francesca, Passamonti, Francesco, Barosi, Giovanni, Silver, Richard T, Hehlmann, Rüdiger, Kiladjian, Jean-Jacques, and Barbui, Tiziano

Published
2022
Full Text
View/download PDF

7. Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus

Author

Buske, C., Dreyling, M., Alvarez-Larrán, A., Apperley, J., Arcaini, L., Besson, C., Bullinger, L., Corradini, P., Giovanni Della Porta, M., Dimopoulos, M., D’Sa, S., Eich, H.T., Foà, R., Ghia, P., da Silva, M.G., Gribben, J., Hajek, R., Harrison, C., Heuser, M., Kiesewetter, B., Kiladjian, J.J., Kröger, N., Moreau, P., Passweg, J.R., Peyvandi, F., Rea, D., Ribera, J.-M., Robak, T., San-Miguel, J.F., Santini, V., Sanz, G., Sonneveld, P., von Lilienfeld-Toal, M., Wendtner, C., Pentheroudakis, G., and Passamonti, F.

Published
2022
Full Text
View/download PDF

8. Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis

Author

Adrián Mosquera-Orgueira, Manuel Pérez-Encinas, Alberto Hernández-Sánchez, Teresa González-Martínez, Eduardo Arellano-Rodrigo, Javier Martínez-Elicegui, Ángela Villaverde-Ramiro, José-María Raya, Rosa Ayala, Francisca Ferrer-Marín, María-Laura Fox, Patricia Velez, Elvira Mora, Blanca Xicoy, María-Isabel Mata-Vázquez, María García-Fortes, Anna Angona, Beatriz Cuevas, María-Alicia Senín, Angel Ramírez-Payer, María-José Ramírez, Raúl Pérez-López, Sonia González de Villambrosía, Clara Martínez-Valverde, María-Teresa Gómez-Casares, Carmen García-Hernández, Mercedes Gasior, Beatriz Bellosillo, Juan-Luis Steegmann, Alberto Álvarez-Larrán, Jesús María Hernández-Rivas, Juan Carlos Hernández-Boluda, and on behalf of the Spanish MPN Group (GEMFIN).

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Abstract

Myelofibrosis (MF) is a myeloproliferative neoplasm (MPN) with heterogeneous clinical course. Allogeneic hematopoietic cell transplantation remains the only curative therapy, but its morbidity and mortality require careful candidate selection. Therefore, accurate disease risk prognostication is critical for treatment decision-making. We obtained registry data from patients diagnosed with MF in 60 Spanish institutions (N = 1386). These were randomly divided into a training set (80%) and a test set (20%). A machine learning (ML) technique (random forest) was used to model overall survival (OS) and leukemia-free survival (LFS) in the training set, and the results were validated in the test set. We derived the AIPSS-MF (Artificial Intelligence Prognostic Scoring System for Myelofibrosis) model, which was based on 8 clinical variables at diagnosis and achieved high accuracy in predicting OS (training set c-index, 0.750; test set c-index, 0.744) and LFS (training set c-index, 0.697; test set c-index, 0.703). No improvement was obtained with the inclusion of MPN driver mutations in the model. We were unable to adequately assess the potential benefit of including adverse cytogenetics or high-risk mutations due to the lack of these data in many patients. AIPSS-MF was superior to the IPSS regardless of MF subtype and age range and outperformed the MYSEC-PM in patients with secondary MF. In conclusion, we have developed a prediction model based exclusively on clinical variables that provides individualized prognostic estimates in patients with primary and secondary MF. The use of AIPSS-MF in combination with predictive models that incorporate genetic information may improve disease risk stratification.

Published
2023
Full Text
View/download PDF

10. Predicting Survival after Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis: Performance of the Myelofibrosis Transplant Scoring System (MTSS) and Development of a New Prognostic Model

Author

Hernández-Boluda, Juan-Carlos, Pereira, Arturo, Alvarez-Larran, Alberto, Martín, Ana-Africa, Benzaquen, Ana, Aguirre, Lourdes, Mora, Elvira, González, Pedro, Mora, Jorge, Dorado, Nieves, Sampol, Antonia, García-Gutiérrez, Valentín, López-Godino, Oriana, Fox, María-Laura, Reguera, Juan Luis, Pérez-Encinas, Manuel, Pascual, María-Jesús, Xicoy, Blanca, Parody, Rocío, González-Pinedo, Leslie, Español, Ignacio, Avendaño, Alejandro, Correa, Juan-Gonzalo, Vallejo, Carlos, Jurado, Manuel, García-Cadenas, Irene, Osorio, Santiago, Durán, María-Antonia, Sánchez-Guijo, Fermín, Cervantes, Francisco, and Piñana, José-Luis

Published
2020
Full Text
View/download PDF

11. DNMT3A/TET2/ASXL1 Mutations are an Age-independent Thrombotic Risk Factor in Polycythemia Vera Patients: An Observational Study.

Author

Segura-Díaz, Adrián, Stuckey, Ruth, Florido, Yanira, Sobas, Marta, Álvarez-Larrán, Alberto, Ferrer-Marín, Francisca, Pérez-Encinas, Manuel, Carreño-Tarragona, Gonzalo, Fox, María L., Tazón Vega, Barbara, Cuevas, Beatriz, López Rodríguez, Juan F., Sánchez-Farías, Nuria, González-Martín, Jesús M., Gómez-Casares, María T., and Bilbao-Sieyro, Cristina

Published
2024
Full Text
View/download PDF

12. Development and validation of a sequential two-step algorithm for the screening of individuals with potential polycythaemia vera

Author

Miguel Piris-Villaespesa, Alberto Álvarez-Larrán, Adolfo Saez-Marín, Claudia Nuñez-Torrón, Gloria Muñoz-Martin, Ricardo Sánchez, Francisco J. del Castillo, Jesús Villarrubia, Javier Lopez-Jimenez, Joaquin Martinez-Lopez, and Valentin Garcia-Gutierrez

Subjects
Medicine, Science
Abstract

Abstract In 2016, the WHO included haemoglobin values within normal ranges as a diagnostic criterion for Polycythaemia Vera (PV). Since then, concerns have arisen that a large number of patients are undergoing unnecessary screening for PV. To address this issue, we estimated the prevalence of JAK2 p.V617F in individuals with elevated haemoglobin or haematocrit and developed and validated a screening algorithm for PV. A total of 15,366 blood counts performed in seven non-consecutive days were reviewed, of which 1001 were selected for subsequent JAK2 p.V617F mutation screening. Eight (0.8%) new JAK2 p.V617F-mutated cases were detected. From ROC curves, a two-step algorithm was developed based on the optimal cut-off for the detection of the JAK2 p.V617F mutation. The algorithm was prospectively validated in an independent cohort of 15,298 blood counts. A total of 1595 (10.4%) cases met the criterion for haemoglobin or haematocrit, of whom 581 passed to step 2 (3.8% of the total). The JAK2 p.V617F mutation was detected in 7 of the 501 patients tested, which accounts for 0.04% of the total cohort and 0.4% of patients with erythrocytosis. In conclusion, this data show that our two-step algorithm improves the selection of candidates for JAK2 p.V617F testing.

Published
2021
Full Text
View/download PDF

15. P1032: REAL-LIFE VALIDATION OF MIPSS70: A RETROSPECTIVE MULTICENTER AND NGS ANALYSIS FROM THE GEMFIN DATABASE

Author

A. Hernández-Sánchez, Á. Villaverde-Ramiro, A. Álvarez-Larrán, E. Arellano-Rodrigo, M. Pérez Encinas, F. Ferrer Marín, E. Such, G. Carreño Gómez-Tarragona, N. de las Heras Rodríguez, M. A. Durán Pastor, M. I. Mata Vázquez, L. Fox, J. M. Raya Sánchez, E. Magro Mazo, M. T. Gómez Casares, M. J. Ramírez Sánchez, B. Xicoy Cirici, Á. Ramírez Páyer, M. J. Fernández Llavador, A. Á. Martín López, A. Mosquera Orgueira, J. Martínez Elicegui, M. Garrote, B. Bellosillo, T. González, J. Hernández-Rivas, and J. C. Hernández Boluda

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2022
Full Text
View/download PDF

16. A novel ETV6::FGFR1 fusion gene in a myeloid/lymphoid neoplasm with FGFR1 rearrangement sensitive to specific FGFR1-2-3 inhibition.

Author

Jiménez-Vicente, Carlos, Garrote, Marta, López-Guerra, Mónica, Villamón, Eva, Guijarro, Francesca, Perez-Valencia, Amanda Isabel, Martinez-Roca, Alexandra, Balaguer, Olga, Álvarez-Larrán, Alberto, Hernández-Boluda, Juan Carlos, Rovira, Montserrat, Colomer, Dolors, Diaz-Beyá, Marina, Rozman, Maria, and Esteve, Jordi

Subjects
GENE fusion, TOXIC epidermal necrolysis, TUMORS, FIBROBLAST growth factor receptors, BLAST injuries, GENETIC testing, DNA analysis
Abstract

This article discusses a rare case of a myeloid/lymphoid neoplasm with FGFR1 rearrangement, specifically the ETV6::FGFR1 fusion gene. The patient initially presented with T-lymphoblastic lymphoma and was treated with chemotherapy, but later relapsed with a mixed phenotype of T-lymphoblastic lymphoma and acute myeloid leukemia. The patient was refractory to various salvage chemotherapy regimens but showed a response to treatment with pemigatinib, a specific FGFR1-2-3 inhibitor. The patient underwent allogeneic hematopoietic stem cell transplantation and maintained a complete response. This case highlights the importance of genetic screening and targeted therapies in the management of myeloid/lymphoid neoplasms with FGFR1 rearrangement. [Extracted from the article]

Published
2024
Full Text
View/download PDF

17. Cytogenetic Assessment and Risk Stratification in Myelofibrosis with Optical Genome Mapping

Author

Such, Álvaro Díaz-González, Elvira Mora, Gayane Avetisyan, Santiago Furió, Rosalía De la Puerta, José Vicente Gil, Alessandro Liquori, Eva Villamón, Carmen García-Hernández, Marta Santiago, Cristian García-Ruiz, Marta Llop, Blanca Ferrer-Lores, Eva Barragán, Silvia García-Palomares, Empar Mayordomo, Irene Luna, Ana Vicente, Lourdes Cordón, Leonor Senent, Alberto Álvarez-Larrán, José Cervera, Javier De la Rubia, Juan Carlos Hernández-Boluda, and Esperanza

Subjects
myelofibrosis, optical genome mapping, chromosome banding analysis, prognosis
Abstract

Cytogenetic assessment in myelofibrosis is essential for risk stratification and patient management. However, an informative karyotype is unavailable in a significant proportion of patients. Optical genome mapping (OGM) is a promising technique that allows for a high-resolution assessment of chromosomal aberrations (structural variants, copy number variants, and loss of heterozygosity) in a single workflow. In this study, peripheral blood samples from a series of 21 myelofibrosis patients were analyzed via OGM. We assessed the clinical impact of the application of OGM for disease risk stratification using the DIPSS-plus, GIPSS, and MIPSS70+v2 prognostic scores compared with the standard-of-care approach. OGM, in combination with NGS, allowed for risk classification in all cases, compared to only 52% when conventional techniques were used. Cases with unsuccessful karyotypes (n = 10) using conventional techniques were fully characterized using OGM. In total, 19 additional cryptic aberrations were identified in 9 out of 21 patients (43%). No alterations were found via OGM in 4/21 patients with previously normal karyotypes. OGM upgraded the risk category for three patients with available karyotypes. This is the first study using OGM in myelofibrosis. Our data support that OGM is a valuable tool that can greatly contribute to improve disease risk stratification in myelofibrosis patients.

Published
2023
Full Text
View/download PDF

24. Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis

Author

Mosquera Orgueira, Adrián, Pérez Encinas, Manuel, Hernández Sánchez, Alberto, González Martínez, Teresa, Arellano Rodrigo, Eduardo, Martínez Elicegui, Javier, Villaverde Ramiro, Ángela, Raya, José María, Ayala, Rosa, Ferrer Marín, Francisca, Fox, María Laura, Velez, Patricia, Mora, Elvira, Xicoy, Blanca, Mata Vázquez, María Isabel, García Fortes, María, Angona, Anna, Cuevas, Beatriz, Senín, María Alicia, Ramírez Payer, Angel, Ramírez, María José, Pérez López, Raúl, González de Villambrosía, Sonia, Martínez Valverde, Clara, Gómez Casares, María Teresa, García Hernández, Carmen, Gasior, Mercedes, Bellosillo Paricio, Beatriz, Steegmann, Juan Luis, Álvarez Larrán, Alberto, Hernández Rivas, Jesús María, Hernández Boluda, Juan Carlos, The Spanish MPN Group (GEMFIN)., Institut Català de la Salut, [Mosquera-Orgueira A, Pérez-Encinas M] Hospital Clínico Universitario, Santiago de Compostela, Spain. [Hernández-Sánchez A, González-Martínez T, Martínez-Elicegui J] Hospital Clínico, Salamanca, Spain. [Arellano-Rodrigo E] Hospital Clínic, Institut d’Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain. [Fox ML] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus

Subjects
Intel·ligència artificial - Aplicacions a la medicina, Pronòstic mèdic, Mielofibrosi, Immunology, Myelofibrosis, Neoplasms::Neoplasms by Histologic Type::Leukemia::Leukemia, Myeloid::Leukemia, Myeloid, Acute [DISEASES], enfermedades hematológicas y linfáticas::enfermedades hematológicas::enfermedades de la médula ósea::trastornos mieloproliferativos [ENFERMEDADES], Cell Biology, Hematology, Prognosis, Biochemistry, Ciencias de la información::metodologías computacionales::algoritmos::inteligencia artificial::aprendizaje automático [CIENCIA DE LA INFORMACIÓN], neoplasias::neoplasias por tipo histológico::leucemia::leucemia mieloide::leucemia mieloide aguda [ENFERMEDADES], Aprenentatge automàtic, Machine learning, Sang - Malalties, Hemic and Lymphatic Diseases::Hematologic Diseases::Bone Marrow Diseases::Myeloproliferative Disorders [DISEASES], Information Science::Computing Methodologies::Algorithms::Artificial Intelligence::Machine Learning [INFORMATION SCIENCE]
Abstract

Aprendizaje automático; Mielofibrosis Aprenentatge automàtic; Mielofibrosi Machine learning; Myelofibrosis Myelofibrosis (MF) is a myeloproliferative neoplasm (MPN) with heterogeneous clinical course. Allogeneic hematopoietic cell transplantation remains the only curative therapy, but its morbidity and mortality require careful candidate selection. Therefore, accurate disease risk prognostication is critical for treatment decision-making. We obtained registry data from patients diagnosed with MF in 60 Spanish institutions (N = 1386). These were randomly divided into a training set (80%) and a test set (20%). A machine learning (ML) technique (random forest) was used to model overall survival (OS) and leukemia-free survival (LFS) in the training set, and the results were validated in the test set. We derived the AIPSS-MF (Artificial Intelligence Prognostic Scoring System for Myelofibrosis) model, which was based on 8 clinical variables at diagnosis and achieved high accuracy in predicting OS (training set c-index, 0.750; test set c-index, 0.744) and LFS (training set c-index, 0.697; test set c-index, 0.703). No improvement was obtained with the inclusion of MPN driver mutations in the model. We were unable to adequately assess the potential benefit of including adverse cytogenetics or high-risk mutations due to the lack of these data in many patients. AIPSS-MF was superior to the IPSS regardless of MF subtype and age range and outperformed the MYSEC-PM in patients with secondary MF. In conclusion, we have developed a prediction model based exclusively on clinical variables that provides individualized prognostic estimates in patients with primary and secondary MF. The use of AIPSS-MF in combination with predictive models that incorporate genetic information may improve disease risk stratification.

Published
2023

26. An analysis of the kinetics of molecular response during the first trimester of treatment with nilotinib in newly diagnosed chronic myeloid leukemia patients in chronic phase

Author

Steegmann, Juan Luis, Colomer, Dolors, Gómez-Casares, Maria-Teresa, García-Gutiérrez, Valentín, Ortí, Guillermo, Ramírez-Payer, Angel, Olavarria, Eduardo, Vall-llovera, Ferrán, Giraldo, Pilar, Conde, Eulogio, Vallansot, Rolando, López-Lorenzo, Jose Luis, Palomera, Luis, Álvarez-Larrán, Alberto, Conesa, Venancio, Bautista, Guiomar, Casas, Laura, Giles, Frank, Hochhaus, Andreas, and Casado-Montero, Luis Felipe

Published
2017
Full Text
View/download PDF

27. MPN-135 Safety and Efficacy of Pelabresib in Combination With Ruxolitinib for JAK Inhibitor-Naïve Patients With Myelofibrosis: Latest Data From the Phase 3 MANIFEST-2 Study

Author

Mascarenhas, John, Rampal, Raajit K., Grosicki, Sebastian, Chraniuk, Dominik, Abruzzese, Elisabetta, Bose, Prithviraj, Gerds, Aaron, Vannucchi, Alessandro M., Palandri, Francesca, Lee, Sung-Eun, Gupta, Vikas, Lucchesi, Alessandro, Oh, Stephen T., Kuykendall, Andrew T., Patriarca, Andrea, Álvarez-Larrán, Alberto, Mesa, Ruben, Kiladjian, Jean-Jacques, Talpaz, Moshe, Lavie, David, Harris, Morgan, Kays, Sarah-Katharina, Maria Jegg, Anna, Wu, Manlei, Brown, Barbara, and Harrison, Claire

Published
2024
Full Text
View/download PDF

28. Safety and Efficacy of Pelabresib in Combination With Ruxolitinib for JAK Inhibitor-Naïve Patients With Myelofibrosis: Latest Data From the Phase 3 MANIFEST-2 Study

Author

Mascarenhas, John, Rampal, Raajit K., Grosicki, Sebastian, Chraniuk, Dominik, Abruzzese, Elisabetta, Bose, Prithviraj, Gerds, Aaron, Vannucchi, Alessandro M., Palandri, Francesca, Lee, Sung-Eun, Gupta, Vikas, Lucchesi, Alessandro, Oh, Stephen T., Kuykendall, Andrew T., Patriarca, Andrea, Álvarez-Larrán, Alberto, Mesa, Ruben, Kiladjian, Jean-Jacques, Talpaz, Moshe, Lavie, David, Harris, Morgan, Kays, Sarah-Katharina, Maria Jegg, Anna, Wu, Manlei, Brown, Barbara, and Harrison, Claire

Published
2024
Full Text
View/download PDF

29. Clinical Characteristics and Outcomes of Patients with Primary and Secondary Myelofibrosis According to the Genomic Classification Using Targeted Next-Generation Sequencing.

Author

Garrote, Marta, López-Guerra, Mónica, Arellano-Rodrigo, Eduardo, Rozman, María, Carbonell, Sara, Guijarro, Francesca, Santaliestra, Marta, Triguero, Ana, Colomer, Dolors, Cervantes, Francisco, and Álvarez-Larrán, Alberto

Subjects
ANEUPLOIDY, GENETIC mutation, POLYCYTHEMIA vera, SEQUENCE analysis, MYELOFIBROSIS, ONCOGENES, HEALTH outcome assessment, ALLELES, GENOMICS, DESCRIPTIVE statistics, RESEARCH funding, SEX chromatin, SYMPTOMS
Abstract

Simple Summary: Myelofibrosis is a heterogeneous disease regarding its mutation landscape as well as its clinical presentation and outcome. A genomic classification with prognostic implications of myeloproliferative neoplasms has been previously proposed, however, this classification has hardly been implemented in myelofibrosis. The aim of our work is to evaluate this genomic classification in a large series of myelofibrosis patients from a single institution, taking into account whether cases are primary or secondary. We found that both primary and secondary myelofibrosis have distinctive molecular landscapes and that genomic profiling provides accurate information regarding prognosis and disease progression. Myelofibrosis (MF) is a heterogeneous disease regarding its mutational landscape, clinical presentation, and outcomes. The aim of our work is to evaluate the genomic classification of MF considering whether it is primary or secondary. One-hundred seventy-five patients, 81 with primary MF (PMF) and 94 with secondary MF (SMF) were hierarchically allocated into eight molecular groups. We found that TP53 disruption/aneuploidy (n = 16, 9%) was more frequent (12% versus 6%) and showed higher allele burden (57% versus 15%, p = 0.01) in SMF than in PMF, and was associated with shorter survival (median 3.5 years). Mutations in chromatin/spliceosome genes (n = 72, 41%) represented the most frequent genomic group in PMF. Homozygous JAK2 mutation (n = 40, 23%) was enriched with old patients with SMF after long-standing polycythemia vera, whereas MF with heterozygous JAK2 mutation (n = 22, 13%) was similarly distributed among PMF and SMF. MF with CALR mutation (n = 19, 11%) predominated in post-essential thrombocythemia MF. The remaining genomic groups were infrequent. TP53 disruption, chromatin/spliceosome mutation, and homozygous JAK2 mutation were associated with significantly shorter survival and higher risk of progression. In conclusion, genomic classification reveals different pathogenic pathways between PMF and SMF and provides relevant information regarding disease phenotype and outcomes. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

30. Protection Against Breakthrough Delta/Omicron Variants in Vaccinated Patients with Myeloproliferative Neoplasms (MPN)

Author

Barbui, Tiziano, Carobbio, Alessandra, Ghirardi, Arianna, Iurlo, Alessandra, De Stefano, Valerio, Sobas, Marta Anna, Rumi, Elisa, Elli, Elena Maria, Lunghi, Francesca, Gasior Kabat, Mercedes, Cuevas, Beatriz, Guglielmelli, Paola, Bonifacio, Massimiliano, Marchetti, Monia, Alvarez-Larran, Alberto, Fox, Laura Maria, Bellini, Marta, Daffini, Rosa, Benevolo, Giulia, Carreño, Gonzalo, Patriarca, Andrea, Al-Ali, Haifa Kathrin, Andrade, Marcio, Palandri, Francesca, Harrison, Claire, Foncillas, Maria Angeles, Osorio, Santiago, Koschmieder, Steffen, Magro, Elena, Kiladjian, Jean-Jacques, Bolaños, Estefanía, Heidel, Florian H., Quiroz, Keina, Griesshammer, Martin, García Gutiérrez, Valentín, Marin Sanchez, Alberto, Hernandez Boluda, Juan Carlos, Lopez Abadia, Emma, Carli, Giuseppe, Sagüés, Miguel, Kusec, Rajko, Xicoy, Blanca, Guenova, Margarita, Navas, Begoña, Angona, Anna, Cichocka, Edyta, Masternak, Anna, Cattaneo, Daniele, Bucelli, Cristina, Betti, Silvia, Borsani, Oscar, Cavalca, Fabrizio, Carbonell, Sara, Curto-Garcia, Natalia, Benajiba, Lina, Rambaldi, Alessandro, and Vannucchi, Alessandro M.

Published
2022
Full Text
View/download PDF

31. Coexisting Myeloproliferative and Lymphoproliferative Neoplasms: A European Multicenter Retrospective Study

Author

Fiallo Suarez, Dolly Viviana Viviana, Stuckey, Ruth, Bilbao, Cristina, Tapia Torres, Maria, Lemes Castellano, Maria Angelina, Fernández-Fuertes, Fernando, Pérez-Ortiz, Leonor, Borsani, Oscar, Rumi, Elisa, Ianotto, Jean-Christophe, Ferrer Marin, Francisca, Gasior Kabat, Mercedes, Cuevas, Beatriz, Lewandowski, Krzysztof, Alvarez-Larran, Alberto, Sobas, Marta Anna, Santoro, Marco, Foncillas, María Ángeles, Drozd-Sokolowska, Joanna, Kandula, Zuzanna, Hernandez Boluda, Juan Carlos, Angona, Anna, Carreño, Gonzalo, Senin, María Alicia, Mata Vazquez, Maria Isabel, Fox, Maria Laura, Del Orbe, Rafael, Velez Tenza, Patricia, Vallansot, Rolando, and Gómez-Casares, María Teresa

Published
2022
Full Text
View/download PDF

32. Toxicity of Asciminib in Real Clinical Practice; Analysis of Side Effects and Cross-Intolerance with Tyrosine Kinase Inhibitors

Author

Pérez-Lamas, Lucía, Luna, Alejandro, Boque, Concepcion, Senin, María Alicia, Xicoy, Blanca, Giraldo, Pilar, Perez Lopez, Raul, Ruiz Nuño, Concepción, De las Heras, Natalia, Mora Casterá, Elvira, Garcia-Hernandez, Carmen, Segura Diaz, Adrian, Steegmann, Juan Luis, Velez Tenza, Patricia, Sanchez-Guijo, Fermin, Garcia-Noblejas Moya, Ana Maria, Juan Vera Goñi, Juan Antonio, Moreno Vega, Melania, Alvarez-Larran, Alberto, Cortes, Montse, Perez Encinas, Manuel, Serrano, Luis, Angona, Anna, Rosell, Ana, Lakhwani, Sunil, Colorado, Mercedes, Ramila, Elena, Cervero, Carlos, Cuevas, Beatriz, Villalon Blanco, Lucia, Hernandez Boluda, Juan Carlos, Paz Coll, Antonio, Gómez García de Soria, Valle, Fernández, Maria Jose, Casado, Luis Felipe, Alonso-Dominguez, Juan Manuel, Anguita Arance, Maria Magdalena, Carrascosa Mastell, Patricia, Salamanca Cuenca, Araceli, Jiménez-Velasco, Antonio, Ramírez, María José, López Esteban, Miguel, Sierra Pacho, Magdalena, Santaliestra, Marta, Alda Alvarez, Olga, de Paz, Raquel, and García Gutiérrez, Valentín

Published
2022
Full Text
View/download PDF

33. Risk of Progression in Chronic Phase-Chronic Myeloid Leukemia (CML) Patients Eligible for Tyrosine Kinase Inhibitor Discontinuation: The Tfr-PRO Study

Author

Zambrotta, Giovanni, Assouline, Sarit, Nicolini, Franck E., Abruzzese, Elisabetta, Miggiano, Maria Cristina, Elena, Chiara, Alvarez-Larran, Alberto, Triguero, Ana, Iurlo, Alessandra, Bucelli, Cristina, Lunghi, Francesca, Capodanno, Isabella, Maffioli, Margherita, Galimberti, Sara, Caocci, Giovanni, Stagno, Fabio, Saussele, Susanne, Fava, Carmen, le Coutre, Philipp, Bonifacio, Massimiliano, Guglielmana, Veronica, Colombo, Federica, Antolini, Laura, and Gambacorti-Passerini, Carlo

Published
2022
Full Text
View/download PDF

35. A polymorphism in the XPD gene predisposes to leukemic transformation and new nonmyeloid malignancies in essential thrombocythemia and polycythemia vera

Author

Hernández-Boluda, Juan-Carlos, Pereira, Arturo, Cervantes, Francisco, Alvarez-Larrán, Alberto, Collado, María, Such, Esperanza, Arilla, M. Jesús, Boqué, Concepción, Xicoy, Blanca, Maffioli, Margherita, Bellosillo, Beatriz, Marugán, Isabel, Amat, Paula, Besses, Carles, and Guillem, Vicent

Published
2012
Full Text
View/download PDF

36. Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera

Author

Alvarez-Larrán, Alberto, Pereira, Arturo, Cervantes, Francisco, Arellano-Rodrigo, Eduardo, Hernández-Boluda, Juan-Carlos, Ferrer-Marín, Francisca, Angona, Anna, Gómez, Montse, Muiña, Begoña, Guillén, Helga, Teruel, Anabel, Bellosillo, Beatriz, Burgaleta, Carmen, Vicente, Vicente, and Besses, Carles

Published
2012
Full Text
View/download PDF

38. Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study

Author

Guglielmelli, Paola, Ghirardi, Arianna, Carobbio, Alessandra, Masciulli, Arianna, Maccari, Chiara, Mora, Barbara, Rumi, Elisa, Triguero, Ana, Finazzi, Maria Chiara, Pettersson, Helna, Paoli, Chiara, Mannelli, Francesco, Vanni, Daniele, Rambaldi, Alessandro, Passamonti, Francesco, Alvarez-Larràn, Alberto, Andreasson, Bjorn, Vannucchi, Alessandro M., and Barbui, Tiziano

Published
2022
Full Text
View/download PDF

45. Correction to: An analysis of the kinetics of molecular response during the first trimester of treatment with nilotinib in newly diagnosed chronic myeloid leukemia patients in chronic phase

Author

Steegmann, Juan Luis, Colomer, Dolors, Gómez-Casares, Maria-Teresa, García-Gutiérrez, Valentín, Ortí, Guillermo, Ramírez-Payer, Angel, Olavarria, Eduardo, Vall-llovera, Ferrán, Giraldo, Pilar, Conde, Eulogio, Vallansot, Rolando, López-Lorenzo, Jose Luis, Palomera, Luis, Álvarez-Larrán, Alberto, Conesa, Venancio, Bautista, Guiomar, Casas, Laura, Giles, Frank, Hochhaus, Andreas, and Casado-Montero, Luis Felipe

Published
2017
Full Text
View/download PDF

46. Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice

Author

Garcia-Gutierrez, Valentin, Luna, Alejandro, Alonso-Dominguez, Juan M., Estrada Barreras, Natalia, Boque, Concepcion, Xicoy, Blanca, Giraldo, Pilar, Angona, Anna, Álvarez Larrán, Alberto, Sanchez-Guijo, Fermin, Ramírez, María José, Mora, Elvira, Vélez, Patricia, Rosell, Ana, Colorado Araujo, Mercedes, Cuevas, Beatriz, Sagüés, Miguel, Cortés, Montserrat, Pérez Encinas, Manuel, Casado Montero, Luis Felipe, Moreno Vega, Melania, Serrano, Luis, Gomez, Valle, Garcia-Hernandez, Carmen, Lakhwani, Sunil, Paz Coll, Antonio, De Paz, Raquel, Suarez-Varela, Sara, Fernandez-Ruiz, Andrés, Perez Lopez, Raul, Ortiz-Fernández, Almudena, Jiménez-Velasco, Antonio, Steegmann-Olmedillas, Juan Luis, Hernandez-Boluda, Juan Carlos, Universitat Autònoma de Barcelona, [Garcia-Gutiérrez V, Luna A] Hematology, Hospital Universitario Ramón y Cajal. IRYCIS, Madrid, Spain. [Alonso-Dominguez JM] Hospital Universitario Fundación Jiménez Díaz, Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD), UAM, Madrid, Spain. [Estrada N, Xicoy B] Institut Català d’Oncologia, Hospital Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Universitat Autònoma de Barcelona, Badalona, Spain. [Boque C] Institut Català d’Oncologia – L’Hospitalet de Llobregat, L’Hospitalet de Llobregat, Spain. [Cortes M] Hospital General de Granollers, Granollers, Spain, and Departament de Salut

Subjects
Adult, Male, Niacinamide, medicine.medical_specialty, Heterocyclic Compounds::Acids, Heterocyclic::Nicotinic Acids::Niacinamide [CHEMICALS AND DRUGS], MEDLINE, Fusion Proteins, bcr-abl, Drug development, Hemic and Lymphatic Diseases::Hematologic Diseases::Bone Marrow Diseases::Myeloproliferative Disorders::Leukemia, Myelogenous, Chronic, BCR-ABL Positive [DISEASES], lcsh:RC254-282, Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Enzyme Inhibitors::Protein Kinase Inhibitors [CHEMICALS AND DRUGS], Young Adult, Text mining, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, hemic and lymphatic diseases, Correspondence, compuestos heterocíclicos::ácidos heterocíclicos::ácidos nicotínicos::niacinamida [COMPUESTOS QUÍMICOS Y DROGAS], Medicine, In real life, Humans, Intensive care medicine, Protein Kinase Inhibitors, Aged, Aged, 80 and over, Leucèmia mieloide crònica - Tractament, business.industry, acciones y usos químicos::acciones farmacológicas::mecanismos moleculares de acción farmacológica::inhibidores enzimáticos::inhibidores de proteínas cinasas [COMPUESTOS QUÍMICOS Y DROGAS], Myeloid leukemia, Hematology, Middle Aged, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Tiroxina - Inhibidors, Clinical Practice, Treatment Outcome, Oncology, Molecularly targeted therapy, Proteïna quinasa CK2, Pyrazoles, Female, enfermedades hematológicas y linfáticas::enfermedades hematológicas::enfermedades de la médula ósea::trastornos mieloproliferativos::leucemia mielogenosa crónica BCR-ABL positiva [ENFERMEDADES], business
Abstract

Chronic myeloid leukemia; Asciminib; Treatment Leucemia mieloide crónica; Asciminib; Tratamiento Leucèmia mieloide crònica; Asciminib; Tractament Despite the excellent overall survival (OS) of chronic myeloid leukemia (CML) patients, a significant proportion will fail currently available tyrosine-kinase inhibitors (TKIs) due to resistance or intolerance. Intolerant patients are usually managed successfully with alternative second-generation tyrosine-kinase inhibitors (2GTKIs). However, more than half of the patients will eventually discontinue second-line treatment due to loss of response or toxicity. Ponatinib is an effective drug in the setting of resistance to 2GTKIs, however with life-threatening side effects and varying responses. Asciminib is a first-in-class STAMP (Specifically Targeting the ABL Myristoyl Pocket) inhibitor that potently and specifically inhibits BCR-ABL1 via binding to a pocket distinct from the ATP binding site of the kinase. Asciminib has the potential to overcome resistance to prior TKIs, and also offers the possibility of dual inhibition of BCR-ABL1 in combination with ATP-binding TKIs. Asciminib has been evaluated in a phase I study in patients with Ph-positive leukemia failing prior TKIs, with promising results. Our aim is to share the first data on the use of asciminib in CML patients in clinical practice, allowed by Novartis under a managed-access program (MAP).

Published
2021

50. Clinical and Molecular Characterization of Triple-Negative Essential Thrombocythemia: Data from the Prospective Spanish Registry of Essential Thrombocythemia

Author

Gil-Manso, Rodrigo, Carreño, Gonzalo, Hernandez Boluda, Juan Carlos, Perez Lopez, Raul, Gómez-Casares, Maria Teresa, Ferrer Marin, Francisca, Arellano-Rodrigo, Eduardo, Angona, Anna, García Gutiérrez, Valentín, Noya, Maria Soledad, Senin, María Alicia, Magro, Elena, Pastor, Irene, Mata, María Isabel, Cuevas, Beatriz, Mora, Elvira, Martinez, Cristina, Alonso-Dominguez, Juan M., Pérez-Encinas, Manuel, Caballero Navarro, Gonzalo, Cortes Vázquez, Miguel A., del Río, Carmen, Martinez Lopez, Joaquin, Ayala, Rosa, and Alvarez-Larran, Alberto

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results